Liquid Biopsy Assays (by LabCE)

1 P.A.C.E. contact hour(s)

(based on 204 customer ratings)

Author: David J. Moffa, PhD, BCLD
Reviewer: Judi Bennett, MT, BSM

Course provided by LabCE.

Liquid biopsy is a rapidly advancing field with a growing number of companies involved in the development of these assays for the diagnosis and stratification of cancer patients. Because liquid biopsy can potentially provide a comprehensive, real-time assessment of the whole tumor burden for an individual patient, many experts believe it has the potential to replace the standard tissue biopsy. This course will discuss the primary molecular biomarkers detected in blood via liquid biopsy assay, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes.

See more courses in: Molecular Pathology

Continuing Education Credits

P.A.C.E.® Contact Hours (acceptable for AMT, ASCP, and state recertification): 1 hour(s)
Course number 578-040-20, approved through 5/31/2022
Florida Board of Clinical Laboratory Personnel Credit Hours - General (Molecular Pathology): 1 hour(s)
Course number 20-778088, approved through 9/1/2022

Objectives

  • Define liquid biopsy testing and review its history.
  • Compare tissue biopsy with liquid biopsy and discuss their advantages and limitations.
  • Define and describe the clinical significance of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes.
  • Review the relationship of CTCs and ctDNA in metastatic disease and understand their potential use in personalized medicine and personalized therapies for cancer.
  • Discuss the technologies involved in liquid biopsy testing and describe some leading commercial methods.

Customer Ratings

(based on 204 customer ratings)

Course Outline

  • Definition and History of Liquid Biopsy Testing
      • Liquid Biopsy: Definition
      • The History of Liquid Biopsy Assays
  • Tissue Versus Liquid Biopsies: Advantages and Limitations
      • Tissue Biopsies
      • Primary Molecular Biomarkers Detected by Liquid Biopsy Assay
      • The Advantages and Limitations of Liquid Biopsies
  • Circulating Tumor Cells (CTCs): Definition and Clinical Significance
      • Circulating Tumor Cells (CTCs): Definition and Clinical Significance
  • Circulating Tumor DNA (ctDNA): Definition and Clinical Significance
      • Circulating Tumor DNA (ctDNA): Definition and Clinical Significance
  • Exosomes: Definition and Clinical Significance
      • Exosomes: Definition and Clinical Significance
  • Liquid Biopsy and Personalized Medicine
      • Personalized Medicine
      • Liquid Biopsy and Personalized Medicine
  • Liquid Biopsy Technology Overview: Commercial Methods
      • Liquid Biopsy Technology Overview
      • The CELLSEARCH® CTC Test
      • The CELLSEARCH® CTC Test: Reports and Interpretation
      • The cobas® EGFR Mutation Test v2
      • Exosome Diagnostics ExoDx™ Lung(ALK)
  • The Future of Liquid Biopsy Testing
      • The Future of the Liquid Biopsy Test:
      • The Future of Liquid Biopsy Test (continued):
  • References
      • References

Additional Information

Level of instruction: Beginning
 
Intended audience: Medical laboratory scientists, medical technologists, and technicians, This course is also appropriate for clinical laboratory science students and pathology residents.
 
Author information: David J. Moffa, PhD, BCLD has over 30 years of experience in the healthcare industry as an executive manager, clinical laboratory director, and medical laboratory scientist. He is currently a technical consultant for Kentmere Healthcare, Wilmington, DE, and until his retirement, was the Regional Director for LabCorp, Inc. He holds a PhD in medical biochemistry from the School of Medicine, West Virginia University.
 
Reviewer information: Judi Bennett, MT, BSM is currently a Program Director for MediaLab, Inc. in Lawrenceville, Georgia. She has over 30 years of medical laboratory experience in an acute care hospital setting as a laboratory manager, senior clinical applications specialist, point-of-care coordinator, microbiology supervisor, and generalist technologist. Judi has experience speaking at various professional conferences and is the author of numerous peer-reviewed publications.
 
Course description: Liquid biopsy is a rapidly advancing field with a growing number of companies involved in the development of these assays for the diagnosis and stratification of cancer patients. Because liquid biopsy can potentially provide a comprehensive, real-time assessment of the whole tumor burden for an individual patient, many experts believe it has the potential to replace the standard tissue biopsy. This course will discuss the primary molecular biomarkers detected in blood via liquid biopsy assay, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes. 

How to Subscribe
MLS & MLT Comprehensive CE Package (by LabCE)
Package of 118 online courses$95
Add to cart
Single online course$20
Add to cart
  • Order for instant access through any computer, any browser.
  • No shipping, faxing, or waiting for certificates.
  • Print or save your certificate of completion as soon as you've completed the course.
  • You'll have 90 days to complete your purchased courses.
Course provided by LabCE.
biopsies shutterstock


Liver biopsy specimen


CTCs_shutterstock



 
ASCLS CE's design and platform are provided by MediaLab, Inc.